International Cannabis Weekly: 321

GERMANY’S CANNABIS ACT (CANG) BILL TAKES ANOTHER STEP FORWARD

Germany’s Cannabis Act (CanG) took another important step forward this week after the first parliamentary debate was held in the Bundestag (German Parliament).

READ MORE  »

NEW YORK CANNABIS REGULATORS EXTEND LICENCE APPLICATION WINDOW 

READ MORE »

ISRAELI CANNABIS COMPANIES NAVIGATE CHALLENGES AMID HAMAS CONFLICT

READ MORE »

• France’s health minister promises continued access to medical cannabis for patients.
• Exploring the realm of medical cannabis in Belgium: Insights from ‘Principles of Clinical Cannabinology’.
• Denmark’s medical cannabis pilot programme witnesses 90% growth in patient numbers within the past year.

• Ukraine’s bid to legalise medical cannabis clears another hurdle, bringing patients one step closer to ‘relief’.

• First UK-grown cannabis-based medicines expected to be available to patients by the end of 2023.

• Medical cannabis factory in Belfast to open next year, becoming Ireland’s first medical cannabis production facility.

READ WEEKLY STOCK REPORT »

• Four new dispensaries set to open in New York following Conditional Adult-Use Retail Dispensary (CAURD) delay.
• New York’s Office of Cannabis Management (OCM) to hold workshops to support cannabis licence applications. 
• Colorado’s legal cannabis sales surpass US$15 billion but monthly slowdown continues.
• Ohio residents begin early in-person voting on the state’s adult-use cannabis legalisation.
• Oregon’s cannabis associations vote unanimously to merge and strengthen the state’s cannabis industry.
• Maryland judge halts ban on CBD shops selling intoxicating hemp-derived products.

BUY NOW AND SAVE »

• Cannabis legalisation in Canada brings societal benefits, yet the public health impact still remains mixed.
• Tilray Medical to support new clinical trial studying medical cannabis in glioblastoma cancer treatment.
• Verano Holdings begins trading on Canada’s Neo Exchange Inc., operating as Cboe Canada.
• Toronto’s GrowerIQ receives more than C$1 million in funding from the government of Canada.
• Canada’s Avant Brands Inc. reports third quarter financial results, disclosing net revenue of C$6.5 million.
• Manitoba judge upholds ban on non-medical homegrown cannabis, citing provincial rights.

COLLABORATE WITH US »

• Project to legalise cannabis for adult use in Colombia overcomes yet another debate.
• Former general director of Anvisa sheds light on how legal actions can lead to the discredit of cannabis treatment.
• João Pessoa City Council approves groundbreaking medicinal cannabis policy bill in Brazil.
• Brazil’s Anvisa to cultivate five thousand cannabis plants, potentially creating the country’s first genetic bank country.

• Sydney’s Endoca Australia rebrands to Aura Therapeutics as the firm broadens its product portfolio.
• Victorian Parliament gives green light for medicinal cannabis driving trial that researches cannabis impairment.
• New Zealand’s Medsafe reclassifies CBD, from a prescription-only medicine to a restricted (pharmacist-only) medicine.
• Bioxyne subsidiary, Breathe Life Sciences (BLS), imports $3.2million of cannabis flower into Australia.

• InterCure Ltd (INCR), based in Israel, delivers the latest update regarding the prevailing security situation in the country.
• Israel’s Ministry of Health grants concessions for medical cannabis patients.